Lenalidomide Fresenius Kabi (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN E3 ubiquitin ligase complex, altering the complex’s substrate specificity. This triggers degradation of transcription factors such as Ikaros and Aiolos, leading to enhanced immune cell activity, inhibition of angiogenesis, and programmed cell death of malignant plasma cells.

The prescribed dose of lenalidomide is individualized by the treating physician based on the specific indication, the patient’s renal function, prior therapies, and overall health status. No universal dosing schedule can be provided; the prescriber sets the regimen according to clinical guidelines and patient factors.

Lenalidomide is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to lenalidomide in its class is thalidomide, while pomalidomide is a newer option. Lenalidomide generally offers a more favorable safety profile than thalidomide, with lower rates of peripheral neuropathy, but it carries a higher risk of cytopenias. Pomalidomide may be used after lenalidomide failure and can provide additional efficacy in certain relapsed cases.

Lenalidomide tablets should be stored at ambient temperature, below 25 °C, in the original blister or bottle. Protect the product from moisture and direct light. Do not store in the refrigerator or freezer, and keep out of reach of children.

Lenalidomide is taken orally as a whole tablet, with or without food, according to the prescriber’s instructions. Patients should swallow the tablet whole with water and avoid crushing or chewing it, unless specifically directed by a healthcare professional.

The most serious adverse events include severe neutropenia or thrombocytopenia, which can lead to life‑threatening infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Additionally, there is a risk of developing secondary primary malignancies, so regular monitoring is essential.

Lenalidomide should be avoided in patients with known hypersensitivity to the drug or its excipients, in pregnant women, and in individuals with severe renal impairment unless dose adjustments are made. Caution is also advised for patients with a history of thromboembolic events or uncontrolled infections.